Your browser doesn't support javascript.
loading
The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.
Chen, Xi; Adhikary, Gautam; Newland, John J; Xu, Wen; Ma, Emily; Naselsky, Warren; Eckert, Richard L.
  • Chen X; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Adhikary G; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Newland JJ; Department of Surgery - Division of Thoracic Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Xu W; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Ma E; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Naselsky W; Department of Surgery - Division of Thoracic Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Eckert RL; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mol Carcinog ; 62(1): 90-100, 2023 01.
Article en En | MEDLINE | ID: mdl-35848131
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Proteína Glutamina Gamma Glutamiltransferasa 2 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Proteína Glutamina Gamma Glutamiltransferasa 2 Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article